Loading...
•
Mar 31
Ultragenyx Q1 2025 Earnings Report
Reported first quarter 2025 financial results and corporate update
Key Takeaways
Ultragenyx reported total revenue of $139 million for the first quarter of 2025, representing 28% growth year-over-year. Net loss improved to $151 million, or $1.57 per share, compared to a net loss of $171 million, or $2.03 per share, in the same period last year. The company reaffirmed its full-year 2025 financial guidance.
Total revenue for Q1 2025 was $139 million, a 28% increase from Q1 2024.
Crysvita revenue in Q1 2025 was $103 million, a 25% increase from Q1 2024.
Net loss for Q1 2025 was $151 million, an improvement from a net loss of $171 million in Q1 2024.
Cash, cash equivalents, and marketable debt securities were $563 million as of March 31, 2025.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Ultragenyx Revenue by Geographic Location
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comEvkeeza Revenue
CapyFin.comMepsevii Revenue
CapyFin.comRevenue by Geographic Location
Latin America and Türkiye Revenue
CapyFin.comU.S. and Canada Revenue
CapyFin.comEurope Revenue
CapyFin.com Forward Guidance
Ultragenyx reaffirmed its full-year 2025 financial guidance, expecting total revenue between $640 million and $670 million, Crysvita revenue between $460 million and $480 million, and Dojolvi revenue between $90 million and $100 million. The company anticipates a reduction in 2025 net cash used in operations compared to 2024.
Positive Outlook
- Total revenue expected to grow approximately 14-20% compared to 2024.
- Crysvita revenue guidance of $460 million to $480 million for 2025.
- Dojolvi revenue guidance of $90 million to $100 million for 2025.
- Expected reduction in 2025 net cash used in operations compared to 2024.
- Prioritizing expense management while investing in commercial launches and Phase 3 programs.
Challenges Ahead
- No specific negative guidance points were explicitly stated in the provided text.